To develop a tumor-microenvironment-responsive, biodegradable hollow MnO2 nanoplatform capable of modulating tissue conditions and delivering drug therapy to promote antitumor immune responses.
Engineered biodegradable hollow MnO2 nanoshells designed for responsive drug release within the tumor microenvironment.
Assessed antitumor therapeutic efficacy of the nanoplatform administered alone and in combination with checkpoint blockade immunotherapy.
Hollow MnO2 nanoshells successfully modulated the local tumor microenvironment to trigger responsive drug release.
Nanoplatform administration achieved significant tumor growth inhibition, with enhanced antitumor activity observed in combination with immune checkpoint blockade.
Abstract
nanoshells able to modulate the tissue microenvironment, release a drug and inhibit tumor growth alone or in combination with check-point blockade therapy.